Revelation Biosciences (REVB) Projected to Release Quarterly Earnings on Thursday

Revelation Biosciences (NASDAQ:REVB) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Revelation Biosciences to announce earnings of ($6.16) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Revelation Biosciences (NASDAQ:REVB) last issued its earnings results on Thursday, August 6th. The company reported ($6.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.12) by $0.03. On average, analysts expect Revelation Biosciences to post ($36.28) EPS for the current fiscal year and ($20.22) EPS for the next fiscal year.

Revelation Biosciences Stock Performance

Revelation Biosciences stock opened at $4.05 on Tuesday. The company has a market capitalization of $2.75 million, a P/E ratio of -0.05 and a beta of -0.07. Revelation Biosciences has a fifty-two week low of $3.08 and a fifty-two week high of $40.60. The stock has a 50-day simple moving average of $5.70 and a 200-day simple moving average of $8.23.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Revelation Biosciences presently has an average rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.